

Zydus receives final approval from the USFDA for Misoprostol Tablets

Ahmedabad, 3 July, 2019

Zydus Cadila has received the final approval from the USFDA to market Misoprostol Tablets (US RLD – Cytotec[®]), 100 mcg and 200 mcg. Misoprostol is used to prevent stomach ulcers in patients taking pain medications especially if the patient is at risk for developing ulcers or has a past history of ulcers. Misoprostol helps to decrease risk of serious ulcer complications such as bleeding. The drug will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

The group now has 268 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
